Scalp psoriasis: European consensus on grading and treatment algorithm

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 12, 2009, Pages 1435-1444

  Ortonne, J P ^a   Chimenti, S ^b   Luger, T ^c   Puig, L ^d   Reid, F ^e   Trueb R M ^f  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c Klinik und Poliklinik fur Hautkrankheiten   (Germany)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HARROGATE DISTRICT HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Consensus; Management; Scalp psoriasis

Indexed keywords

ALEFACEPT; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; COAL TAR; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; INFLIXIMAB; KETOCONAZOLE; METHOTREXATE; PLACEBO; PSORALEN; RETINOID; SALICYLIC ACID; SELENIUM SULFIDE;

ALGORITHM; ALLERGIC REACTION; CLINICAL TRIAL; CONFERENCE PAPER; CUSHING SYNDROME; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRY SKIN; DYSPNEA; ERYTHEMA; EXCIMER LASER; GEL; GLAUCOMA; HAIR COLOR; HAIR DISCOLORATION; HAIR LOSS; HAIR TEXTURE; HUMAN; HYPERCALCEMIA; LOTION; OINTMENT; PATIENT COMPLIANCE; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUSTULE; RASH; SCALP; SCALP PSORIASIS; SIDE EFFECT; SKIN ABRASION; SKIN ATROPHY; SKIN DISCOLORATION; SKIN IRRITATION; TELANGIECTASIA;

ALGORITHMS; DERMATOLOGIC AGENTS; EUROPE; HUMANS; PSORIASIS; SCALP DERMATOSES;

EID: 70449504767     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03372.x     Document Type: Conference Paper

References (56)

1. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001 2 : 159 165.
2. van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998 197 : 326 334.
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 : 280 284.
4. Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol 2007 21 : 1151 1160.
5. Williams RE. Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists. BMJ 1991 303 : 829 835.
6. Nast A, Kopp I, Augustin M et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007 5 (Suppl. 3 1 119.
7. Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 2000 61 : 725 733, 736.
8. Snellman E. Psoriasis. Finnish Medical Society, Helsinki, Finland, 2005.
9. British Association of Dermatologists. Psoriasis Guideline. British Association of Dermatologists, London, UK, 2006.
10. Menter A, Reich K, Shu L, Guzzo C. Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: results from controlled clinical trials. J Am Acad Dermatol 2008 58 : Abstract 120.
11. Krell J, Nelson C, Spencer L, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol 2008 58 : 609 616.
12. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002 146 : 351 364.
13. Lassus A. Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone-17,21-dipropionate: a double-blind comparison. Curr Med Res Opin 1976 4 : 365 367.
14. Hovding G. Treatment of psoriasis of the scalp with betamethasone 17,21-dipropionate plus salicylic acid lotion ('Diprosalic'). Pharmatherapeutica 1981 3 : 61 66.
15. Langner A, Wolska H, Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983 32 : 290 296.
16. Green C, Ganpule M, Harris D et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994 130 : 483 487.
17. Klaber MR, Hutchinson PE, Pedvis-Leftick A et al. Comparative effects of calcipotriol solution (50 micrograms/mL) and betamethasone 17-valerate solution (1 mg/mL) in the treatment of scalp psoriasis. Br J Dermatol 1994 131 : 678 683.
18. Katz HI, Lindholm JS, Weiss JS et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995 17 : 390 401.
19. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, Abdulla SA. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000 20 : 65 68.
20. Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3396 patients. Dermatology 2001 203 : 153 156.
21. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004 3 : 367 373.
22. Andreassi L, Giannetti A, Milani M. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis. An open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003 148 : 134 138.
23. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003 72 : 407 411.
24. Reygagne P, Mrowietz U, Decroix J et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005 16 : 31 36.
25. Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006 17 : 90 95.
26. Mazzotta A, Esposito M, Carboni I, Schipani C, Chimenti S. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat 2007 18 : 84 87.
27. Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008 217 : 107 113.
28. Jemec GB, Ganslandt C, Ortonne JP et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008 59 : 455 463.
29. Luger TA, Cambazard F, Larsen FG et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008 217 : 321 328.
30. van de Kerkhof PC, Hoffmann V, Anstey A et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009 160 : 170 176.
31. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003 7 : 185 192.
32. Poulin Y, Papp K, Bissonnette R et al. Safe and effective long-term control of moderate scalp psoriasis with clobetasol propionate shampoo 0.05%. Manuscript in preparation 2008.
33. Downs AM. Dovobet ointment under occlusion overnight for troublesome scalp psoriasis. Acta Derm Venereol 2006 86 : 57 58.
34. Andres P, Poncet M, Sidou F, Soto P. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol 2006 5 : 328 332.
35. Reygagne P, Poncet M, Sidou F, Soto P. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. Cutis 2007 79 : 397 403.
36. Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis 2007 80 (5 Suppl 12 19.
37. Ruzicka T, Trompke C. [Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion]. Hautarzt 2004 55 : 165 170 (in German).
38. Going SM, Guyer BM, Jarvie DR, Hunter JA. Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol 1986 11 : 260 262.
39. Fysh JM, Andrews LS, Pohl LR, Nebert DW. Differing degrees of coal-tar shampoo-induced mutagenesis in the Salmonella/liver test system in vitro. Pharmacology 1980 20 : 1 8.
40. Merk HF, Mukhtar H, Kaufmann I, Das M, Bickers DR. Human hair follicle benzo[a]pyrene and benzo[a]pyrene 7,8-diol metabolism: effect of exposure to a coal tar-containing shampoo. J Invest Dermatol 1987 88 : 71 76.
41. Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993 29 : 1008 1012.
42. Farr PM, Krause LB, Marks JM, Shuster S. Response of scalp psoriasis to oral ketoconazole. Lancet 1985 2 : 921 922.
43. Rosenberg EW, Belew PW. Improvement of psoriasis of the scalp with ketoconazole. Arch Dermatol 1982 118 : 370 371.
44. Schoket B, Horkay I, Kósa A et al. Formation of DNA adducts in the skin of psoriasis patients, in human skin in organ culture, and in mouse skin and lung following topical application of coal-tar and juniper tar. J Invest Dermatol 1990 94 : 241 246.
45. Borska L, Fiala Z, Krejsek J et al. Cytogenetic and immunological changes after dermal exposure to polycyclic aromatic hydrocarbons and UV radiation. Physiol Res 2006 55 : 317 323.
46. van Schooten FJ, Moonen EJ, Rhijnsburger E, van AB, Thijssen HH, Kleinjans JC. Dermal uptake of polycyclic aromatic hydrocarbons after hairwash with coal-tar shampoo. Lancet 1994 344 : 1505 1506.
47. Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol 2002 138 : 803 807.
48. Housman TS, Mellen BG, Rapp SR, Fleischer AB Jr, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 2002 70 : 327 332.
49. Tan J, Thomas R, Wang B. Treatment of scalp psoriasis with short-contact clobetasol propionate shampoo 0.05% results in high patient satisfaction and quality of life improvement. Manuscript in preparation 2008.
50. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999 41 : 581 583.
51. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 244.
52. Feldman SR, Clark AR, Venkat AP, Fleischer AB Jr, Anderson RT, Rajagopalan R. The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol 2005 152 : 382 383.
53. Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J 2004 10 : 7.
54. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol 2004 51 : 563 569.
55. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003 2 : 260 266.
56. Cardenas EL, de Arruda LF, Abulafia LA, Gonzales VS. Efficacy and safety of efalizumab in adults with moderate to severe plaque psoriasis and hand and foot involvement: a prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America (Abstract). J Am Acad Dermatol 2008 58 : AB131.